Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Type 1 Von Willebrand Disease: The VWD Minimize Study
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Von Willebrand factor (Primary) ; Tranexamic acid
- Indications Von Willebrand disease
- Focus Therapeutic Use
- Acronyms VWDMin
- 21 Aug 2017 Planned End Date changed from 1 Jun 2022 to 15 Aug 2022.
- 21 Aug 2017 Planned primary completion date changed from 1 Jun 2022 to 15 Aug 2022.
- 21 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 15 Aug 2018.